Khondrion

About:

Khondrion is a clinical-stage pharmaceutical company.

Twitter/X: khondrion

Top Investors: EASME - EU Executive Agency for SMEs, Mito Fund

Description:

Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, the company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.

Total Funding Amount:

3.34M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Nijmegen, Gelderland, The Netherlands

Founded Date:

2012-01-01

Founders:

Jan Smeitink

Number of Employees:

11-50

Last Funding Date:

2024-11-21

IPO Status:

Private

Industries: